Evercrisp Biosciences is innovating at the molecular level to enable precise, safe, and scalable delivery of genetic therapies into target tissues. Evercrisp applies proprietary technologies from world-renowned scientific founders to design miniproteins that can access brain, kidney, muscle, and other tissues previously unreachable by genetic medicines. Evercrisp miniproteins are “self-delivering” – they do not require assisted delivery via LNPs, viral vectors, or other vehicles that can trigger immune responses.